Press Releases Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2025-05-23 am EDT			5-day change	1st Jan Change
442.95 ^DKK	-0.75%		+3.84%	-29.04%

May. 23	The EU's top exports, most vulnerable to Trump's new tariffs	RE
May. 23	Americans scramble as weight-loss drug discounts fall short, copies face crackdown	RE

Press Releases

From Retina Scans to Cancer Trials, AI Is Taking Over the Exam Room	May. 20	AQ
Novo Nordisk CEO resigns due to increased competitive pressure in obesity drug market	May. 17	AQ
Novo Nordisk CEO to exit role	May. 16	AQ
CEO of Novo Nordisk, maker of weight loss drug Wegovy, to step down in wake of share price drop	May. 16	AQ
Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk	May. 16	GL
Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk	May. 16	GL
Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases	May. 14	GL
Kasso e-methanol facility officially inaugurated; The world's first large-scale commercial e-methanol facility	May. 13	AQ
Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE	May. 12	GL
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs	May. 11	AQ
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons	May. 09	GL
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons	May. 09	AQ
Novo Nordisk: Q1 Earnings Snapshot	May. 07	AQ
Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025	May. 07	GL
Novo Nordisk A/S : Minutes and voting results from Annual General Meeting 2025	Apr. 24	PU
FDA Issues Warning About Counterfeit Ozempic	Apr. 22	AQ
FDA warns of fake Ozempic Type 2 diabetes injection drugs	Apr. 14	AQ
Novo Nordisk A/S : 2024 ( novo nordisk modern slavery statement 2024 )	Apr. 14	PU
Novo Nordisk A/S : 2024 ( novo nordisk human rights report 2024 )	Apr. 14	PU
Nanexa publishes annual report for 2024	Apr. 10	AQ
Canadian scientist wins Breakthrough Prize for discovery of hormone used in Ozempic, Mounjaro	Apr. 05	AQ
Next-gen biotech: rBIO's approach to affordable insulin solutions	Apr. 04	AQ
Novo Nordisk announces changes in Executive Management	Apr. 03	GL
Novo Nordisk A/S : Presentation from Annual General Meeting 2025	Mar. 31	PU
Novo Nordisk gains rights to novel small molecule inhibitor	Mar. 31	AQ